In 2023, 42% of the EBITDA was delivered in Q4, reflecting the seasonality of the business. Management emphasized that growth in ‘24 will again be back-end loaded. Hence, we expect Q1 to be broadly in line with last year.Growth engines are expected to continue their progression in '24 with significant top-line and profitability growth in DPC. Profitability will continue to improve in Healthcare IT although we should not see a huge step up yet. Radiology, however, is not expected to recover ...
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
Founded in 1959, Leifheit AG is one of the leading European brand suppliers of household items. The group divides its operating business into the household, wellbeing and private label segments. In view of its growing turnover (CAGR of +2.8% for 2023 to 2026e) and EBIT margins (+290bp to 5.2% in 2026e vs 2023), as well as its solid financial profile (equity ratio of about 50%, average net cash position of c. € 40m for 2024e to 2026e, average positive FCF of c. € 11m for 2024e to 2026e...
>Solid cash position - Galapagos reported its Q1 earnings after the close in the US. Group revenues came in at € 100m vs € 83m expected. The bulk stemmed from its agreement with Gilead for € 62m while net product sales amounted to € 37m. At the operating level, costs were broadly under control, with total expenditure of around € 129m vs € 110m although we note an increase of close to 36% in R&D expense due to the development of the clinical portfolio. In contrast...
>Une trésorerie solide - Galapagos publiait après la fermeture du marché US ses résultats du T1. Les revenus du groupe ressortent ainsi à 100 M€ vs 83 M€ att. L’essentiel des revenus vient de son accord avec Gilead pour 62 M€ alors que les ventes des produits nets ressortent à 37 M€. Au niveau opérationnel, les coûts sont globalement bien maitrisés ce qui conduit à avoir des dépenses totales de l’ordre de 129 M€ vs 110 M€ même si nous observons une hausse de près...
Galapagos reported uneventful 1Q24 results and confirmed its FY24 cash burn guidance of € 280-320m (FY23: € 414.8m), thanks to the savings from the transfer of Jyseleca to Alfasigma. While the company did not provide an update on timelines for its pipeline, we think data updates from the phase 1/2 CAR-T trials in r/r NHL and r/r CLL could come at upcoming scientific conferences (e.g. ASH in December 2024). Beyond that, BD remains on the table and we'd like to see an acceleration on that front wi...
GLPG published its Q1 results, reporting Group net revenues of EUR 100m, in line with CSS. Net profit was significantly up (but below CSS), notably boosted by preliminary calculation of the gain on the sale of Jyseleca.FY24 reduced cash burn guidance reiterated. Nothing new on the CAR-T front. Yet, it is good to see that the company still plans to submit IND applications for its CAR-Ts still in 2024. Remember that GLPG has been running CAR-T trials in Europe only so far.Overall, no material surp...
Galapagos reports first quarter 2024 financial results Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs in oncology and immunologyExecuted agreements with BridGene Biosciences and Thermo Fisher Scientific, and investment in Frontier MedicinesTransferred Jyseleca® business to Alfasigma S.p.A., freeing up resources to invest in growth areasGroup net revenues in the first quarter of €100 millionCash and current financial investments of €3.6 billion on 31 March 2024Reconfirmed 2024 cash burni guidance o...
Galapagos rapporteert financiële resultaten voor het eerste kwartaal 2024 Vooruitgang met potentiële best-in-class R&D pijplijn van celtherapie en kleine moleculen, met vier klinische assets en >15 onderzoeksprogramma's in oncologie en immunologie Overeenkomsten afgesloten met BridGene Biosciences en Thermo Fisher Scientific, en investering in Frontier MedicinesJyseleca® business overgedragen aan Alfasigma S.p.A., waardoor middelen vrijkomen om te investeren in groeigebiedenNetto groepsomzet in het eerste kwartaal van €100 miljoenGeldmiddelen en kortlopende financiële investeringen van €...
In this May edition of our Dynamic Top Pick List we replace Arcadis by Fugro. Arcadis continues to deliver consistently on its promises and is working hard to realise its 2026 margin targets via cross selling, leveraging its global engineering platform and numerous self-help measures. In spite of this we remove Arcadis from our Dynamic Top Pick List as the recent & strong share price performance leaves little room for further short term triggers As a service provider to the energy industry, Fu...
Galapagos’ shareholders adopt all resolutions proposed by the Board of Directors at the Annual and Extraordinary Shareholders Meetings 2024 Mechelen, Belgium; 30 April 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the company’s Annual and Extraordinary Shareholders’ Meetings (AGM and EGM) held on 30 April 2024 were approved. The AGM approved, amongst other items: The Remuneration Report and revised Remuneration PolicyThe remuneration of the members of the Board of DirectorsThe reappointment of Dr. Elisabeth Svanberg as Independent...
Galapagos’ aandeelhouders keuren alle door de Raad van Bestuur voorgestelde besluiten goed op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen 2024 Mechelen, België; 30 april 2024; 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) maakt vandaag bekend dat alle voorstellen tot besluit op de jaarlijkse Gewone en Buitengewone Algemene Aandeelhoudersvergaderingen van 30 april 2024 zijn goedgekeurd. De jaarlijkse Gewone Algemene Aandeelhoudersvergadering keurde onder meer goed: Het Remuneratieverslag en gewijzigde RemuneratiebeleidDe bezoldiging van de BestuurdersDe he...
BioSenic S.A. : Information on the total number of voting rights and shares PRESS RELEASE – REGULATED INFORMATION Mont-Saint-Guibert, Belgium, April 30, 2024, 7.00 am CEST – (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares. The following information is published in accordance with Article 15 of the Belgian law of 2 May 2007 on the publication of major shareholdings in issuers...
Participation notification by UBS Group AG Brussels, April 29, 2024, 08:30 CEST - Regulated information In line with Belgian transparency legislation (Law of May 2, 2007), UBS Group AG recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 5%. The notification, dated April 23, 2024, contains the following information: Reason for the notification: acquisition or disposal of financial instruments that are treated as voting securities. Notified by: A parent undertaking or a controlling person Date on which the threshold is ...
Notification de participation par UBS Group AG Bruxelles, le 29 avril 2024 - 08h30 CET - Information régulée Conformément à la législation et réglementation en matière de transparence financière (loi du 2 mai 2007), UBS Group AG a envoyé récemment à Solvay la notification de transparence suivante indiquant avoir franchi le seuil de 5%. La notification, datée du 23 avril 2024, contient l’information suivante: Motif de la notification: acquisition ou cession d’instruments financiers conférant le droit de vote. Notification par: une entreprise-mère ou une personne détenant l...
Participatiemelding van UBS Group AG Brussel, 29 april 2024 - 8u30 CET - Gereglementeerde informatie In overeenstemming met de Belgische transparantiewetgeving (Wet van 2 mei 2007) heeft UBS Group AG onlangs de volgende transparantiekennisgeving naar Solvay gestuurd om aan te geven dat ze de drempel van 5% heeft overschreden. De kennisgeving, gedateerd 23 april 2024, bevat de volgende informatie: Reden voor de kennisgeving: verwerving of overdracht van stemrechtverlenende effecten Kennisgeving door: een moederonderneming of een controlerende persoon Datum waarop de drempel ...
Q1 was in line with expectations whereby volume growth was able to curb the persist price deflationNo rebound yet in newbuild but renovation is able to curb thisAll in all, we stick to our neutral stance and set our TP at EUR 12.0/share or 9x EV/EBITDA (2025e)
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.